Olaparib Dose Escalation in Combination With High Dose Radiotherapy to the Breast Andregional Lymph Nodes in Patients With Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Breast cancer; Inflammatory breast cancer
- Focus Adverse reactions
- 28 Sep 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2020.
- 28 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Jan 2019.
- 08 Oct 2015 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018, as reported by ClinicalTrials.gov record